Neumedicines

Neumedicines Receives $8.8 Million in BARDA Funding for Second Supportive Species Studies in Mice to Support the Development of HemaMax™ for HSARS

PASADENA, Calif. (September 1, 2012) – Neumedicines Inc., a privately held company developing therapies based on Interleukin-12 (IL-12) as a radiation medical countermeasure and for the treatment of chemotherapy-induced thrombocytopenia, announces that it has received $8.8 million from the U.S. Government's Biomedical Advanced Research & Development Authority (BARDA) to conduct studies with murine IL-12 in mice as a second supportive species as required by the Animal Rule for the hematopoietic syndrome of acute radiation syndrome (HSARS) indication. To date, Neumedicines has received a total of $41 million from BARDA for the development of HemaMax™ as a countermeasure for radiation exposure.

"We appreciate BARDA's ongoing support in advancing the development of HemaMax™ for HSARS," said Neumedicines President and Chief Executive Officer Lena Basile, J.D., Ph.D. "We intend to include results from these murine model studies required by the Animal Rule in support of our submission for U.S. Food and Drug Administration approval for HemaMax™ under a Biologics License Application (BLA)."

Preclinical and clinical studies have been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contracts No. HHSO1002000800060C and No. HHSO100201100037C

About HemaMax™ (rHuIL-12)
HemaMax™ (NMIL12-1) is based on rHuIL-12 (recombinant human interleukin–12). Scientists from Neumedicines discovered the previously unexplored hematological properties of IL-12 by demonstrating the potent survival effects of single, low-dose IL-12 on hematopoietic recovery following lethal radiation. HemaMax™ is a new therapeutic that is predicted to be administered to humans in very low, nanogram per kilogram doses to achieve potent radiomitigation effects. To date, Neumedicines has demonstrated that HemaMax™ can increase survival in mice and non-human primates who receive the therapeutic in single, low doses 24 hours after lethal radiation exposure.

About Neumedicines Inc.
Neumedicines Inc. is developing protein therapeutics that address unmet clinical and societal needs in the fields of oncology, hematology and immunology. The company's lead product candidate is HemaMax™ (recombinant human interleukin-12, or rHuIL-12), which functions by targeting multiple pathways of hematopoiesis and innate immunity. HemaMax™ is being development as a biodefense radiation medical countermeasure and for indications in oncology, initially for chemotherapy-induced thrombocytopenia. Neumedicines is committed to developing and maximizing the scientific, clinical and commercial potential of its product pipeline. For more information, please visit www.neumedicines.com or follow the Company on Twitter @Neumedicines.

# # #